BioMarin Pharmaceutical — Oct 29, 2024 release

The updated guidance highlights the sustained strong demand for VOXZOGO and growth trajectory of Enzyme Therapies, as well as BioMarin's commitment to expand profitability while investing in innovation. • During the quarter, BioMarin reaffirmed long-term guidance and outlook previously provided at Investor Day on September 4, 2024, targeting: ◦ Approximately $4 billion in Total Revenues in 2027; ◦ 40% Non-GAAP Operating Margin (1) starting in 2026 and growing to the low- to mid-40% range over time; ◦ More than $1.25 billion operating cash flow per year starting in 2027; ◦ Mid-teen compound annual growth rate (CAGR) for total revenues through 2034; and ◦ Treatments for Skeletal Conditions to represent a greater than $5 billion revenue opportunity over time. (1) Refer to Non-GAAP Information beginning on page 10 of this press release for a complete discussion of the company’s Non-GAAP financial information. Reconciliation of forward-looking Non-GAAP financial measures to the comparable information reported under U.S. GAAP is not available. Refer to Forward-Looking Non-GAAP Financial Information on page 5 for further information. 3 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 % Change 2024 2023 % Change Total Revenues $746 $581 28% $2,107 $1,773 19% Net Product Revenues by Product: VOXZOGO $190 $123 54% $527 $324 63% VIMIZIM $178 $159 12% $549 $526 4% NAGLAZYME $132 $109 21% $370 $322 15% PALYNZIQ $91 $79 15% $255 $216 18% ALDURAZYME $